Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Recently Lilly announced acquisition of Versanis lead obesity candidate bimagrumab, a monoclonal antibody targeting activin type II receptors to inhibit atrophy and to increase muscle mass (142144)
PMCID: PMC10844538.
However, like most medications, GLP-1s come with potential side effects
The information provided in this article reflects the current situation as of June 18, 2025
US$ 21.86
US$ 26.22
US$ 27.30
US$ 22.12
US$ 23.50
US$ 24.23
US$ 28.89
